MIAMI--(BUSINESS WIRE)--Bio-Nucleonics, Inc., a life sciences Company, specializing in the development and manufacture of radiopharmaceuticals, medical devices and imaging agents, will be attending the Society of Nuclear Medicine (SNM) Annual Meeting, held in San Antonio, TX, June 4th through 8th, 2011.
The Company announced that it has resumed production of the cancer drug Strontium Chloride Sr-89 Injection USP (“Strontium-89”). Strontium-89 is an intravenously administered cancer drug that provides long lasting pain relief for patients suffering from bone pain due to metastatic cancer, typically caused by advanced stage breast, prostate or lung cancer.
